Results 201 to 210 of about 745,289 (215)

Factors Involved in the Design of Cytotoxic Payloads for Antibody–Drug Conjugates

2012
Selective targeting of cancer can be accomplished by the use of monoclonal antibodies (mAbs) that bind to tumor-associated antigens expressed preferentially on the surface of cancer cells. Several of these non-derivatized antibodies, or naked antibodies, have been approved for the treatment of various cancer types.
Wayne C. Widdison, Ravi V. J. Chari
openaire   +1 more source

The Use of α-fetoprotein for the Delivery of Cytotoxic Payloads to Cancer Cells

Therapeutic Delivery, 2014
One approach to improving the activity of anticancer drugs is to bind them to the human α-fetoprotein (HAFP) that recognizes the tumor-associated cell-surface HAFP receptor. A drug can be bound to the HAFP by covalent conjugation or within a non-covalent complex.
openaire   +2 more sources

Abstract 1646: Highly cytotoxic, completely human constructs targeting HER2 and containing the immuno-oncology payload granzyme B

Cancer Research, 2017
Abstract Recent immunotherapeutic approaches designed to augment T- and B-cell mediated killing of tumor cells has met with clinical success suggesting that immuno-oncology (IO) approaches have tremendous potential for treatment in a broad spectrum of tumor types.
Lawrence H. Cheung, Yunli Zhao, Khalid A. Mohamedali, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum   +5 more
openaire   +1 more source

Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy.

Bioorganic & Medicinal Chemistry Letters, 2019
Uncialamycin analogs were evaluated as potential cytotoxic agents in an antibody-drug conjugate (ADC) approach to treating human cancer. These analogs were synthesized using Hauser annulations of substituted phthalides as a key step.
N. Chowdari, Chin Pan, Chetana Rao, D. Langley, P. Sivaprakasam, B. Sufi, Dan Derwin, Yichong Wang, E. Kwok, D. Passmore, V. Rangan, S. Deshpande, P. Cardarelli, G. Vite, S. Gangwar   +14 more
semanticscholar   +1 more source

Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo.

Bioconjugate chemistry, 2019
This work discloses the first examples of antibody-drug conjugates (ADCs) that are constructed from linker-drugs bearing dimeric seco-CBI payloads (duocarmycin analogs).
Dian Su, Jinhua Chen, Ely Cosino, Josefa dela Cruz-Chuh, Helen Davis, Geoffrey Del Rosario, I. Figueroa, Leanne H. Goon, Jintang He, A. Kamath, S. Kaur, K. Kozak, J. Lau, Donna W. Lee, M. V. Lee, D. Leipold, Luna Liu, Peter S. Liu, Guo‐Liang Lu, C. Nelson, Carl Ng, Thomas H. Pillow, P. Polakis, A. Polson, Rebecca K Rowntree, Ola M. Saad, B. Safina, N. Stagg, M. Tercel, R. Vandlen, B. Vollmar, J. Wai, Tao Wang, Binqing Wei, Keyang Xu, Juanjuan Xue, Zijin Xu, Gang Yan, Hui Yao, Shang‐Fan Yu, Donglu Zhang, Fiona Zhong, P. Dragovich   +42 more
semanticscholar   +1 more source

Abstract 2056: Click chemistry enabled selective activation of highly cytotoxic MMAE payload at tumors using TROP2 targeting agent

Cancer Research
Abstract Shasqi is advancing the Click Activated Protodrugs Against Cancer (CAPAC®) platform based on click chemistry, a Nobel Prize winning technology. The platform is modular and comprises 1) an activator that target specific antigens, and 2) inert cancer drugs, protodrugs, which are selectively activated at tumors via click chemistry.
George Coricor, Jesse M. McFarland, Sangeetha Srinivasan, Stefanie Wagner, Tri-Hung Nguyen, Jose M. Mejia Oneto   +5 more
openaire   +1 more source

Abstract 314: Improved tumor penetration and cytotoxic payload release with TD001, a novel PSMA-targeting ADC with optimized linker-payload composition, in PSMA-expressing CRPC CDX castrated mouse models

Cancer Research
Abstract Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein belonging to the folate receptor family, is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), and increases following androgen deprivation therapy (ADT).
Daniela Impellizzieri, Elisa Storelli, Atik Balla, Simone Mosole, Cristina Dongilli, Federico Jauk, Roberta Frapolli, Lavinia Morosi, Maurizio D'Incalci, Jemila Houacine, Morris Rosenberg, Bérangère Deleglise, Esteban Cvitkovic, Carlo V. Catapano   +13 more
openaire   +1 more source

Antibody Drug Conjugates with a Novel Translation Inhibitor Payload Demonstrate Cytotoxicity and Tumor Growth Reduction in Multiple Myeloma Models

Blood
Background Antibody drug conjugates (ADCs) are a validated modality for the targeted delivery of cytotoxic payloads to myeloma cells while sparing healthy tissue. To achieve the full potential of ADCs in multiple myeloma patients, it will be important to have ADCs that incorporate payloads with ...
openaire   +1 more source

Development of novel cryptophycins as cytotoxic payloads for tumor targeting

2022
Schachtsiek, Thomas, Dessin, Cedric, Sewald, Norbert   +2 more
openaire   +1 more source

Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates.

Bioconjugate chemistry, 2017
J. Sadowsky, Thomas H. Pillow, Jinhua Chen, Fang Fan, Changrong He, Yanli Wang, Gang Yan, Hui Yao, Zijin Xu, Shanique Martin, Donglu Zhang, Phillip Y Chu, Josefa dela Cruz-Chuh, Aimee O'Donohue, Guangmin Li, Geoffrey Del Rosario, Jintang He, Luna Liu, Carl Ng, Dian Su, Gail D Lewis Phillips, K. Kozak, Shang‐Fan Yu, Keyang Xu, D. Leipold, J. Wai   +25 more
semanticscholar   +1 more source